D-DIMER A RISK FACTOR ASSOCIATED WITH C-REACTIVE PROTEIN FOR PREDICTING THE SEVERITY OF INFECTION BY COVID-19
Background: COVID-19, caused by SARS-CoV-2, has unresolved mortality risk factors and clinical course, highlighting the need for further research. Aims: The study aimed to asses D-dimer and C-Reactive Protein (CRP) as the risk factors for severity covid-19 and who are less capable of surviving. Methods: A retrospective study conduct of COVID-19 in adult inpatients aged >20 at Al-sadder and Alamal Hospital in Iraq. Demographics, clinical trials, treatments, and viral RNA samples were analyzed. The study involved 100 patients, with 67 discharged and 33 hospitalized died. The majority of the participants 45% were aged < 40, but 55% were aged >40 years. Results: A significant and 57% were male 37(55.2%) Survivor vs. 20 (60.6%) non-survivor, p=0.024), more than 43% were female (30(44.8%) Survivor vs. 13(39.4%) non-survivor, p=0.010. Patients had underlying comorbidities (66%), survivor 37(55%), and non-survivor 29(87%). The most prominent comorbidity in non-survivors more than survivors was diabetic mellitus 85%, asthma 58%, stroke 48%, renal failure 42%, heart strake 33%, and hypertension 18%. The study found significant differences in WBC, lymphocyte count, D-dimer, Ferritin, CRP, and LDH levels in non-survivors compared to survivor patients, with a positive correlation between D- dimer and these parameters. The ROC analysis curve showed CRP with a high AUC of 80.2%, 87.9% sensitivity, and 37.3% specificity, while D-dimer and LDH had AUCs of 0.74.9 and 70%, respectively. Discussion: The study found that older age, higher d-dimer, ferritin, CRP, and LDH are associated with disease severity and higher mortality risk in adult COVID-19 patients. Conclusions: These biomarkers could aid in early detection of disease progression signs and better patient management
Read ArticleASSESSMENT OF SERUM SCLEROSTIN LEVEL AS A BIOMARKER ASSOCIATED WITH BONE DISORDERS IN Β-THALASSEMIA PATIENTS IN AL- NAJAF CITY, IRAQ
Background: β-thalassemia is a blood disorder in which the body does not make hemoglobin normally. Aim: To assess serum sclerostin in female patients with beta-thalassemia and compare with the healthy controls and to predict its complication associated with the bone pathophysiology, for designed improvement the lifestyle goodliness for these patients. Material and methods: Sixty-nine female beta-thalassemia (βT) patients (54 βT major and 15 βT Intermedia), aged 8-40 years who dependent on transfused blood, and 20 healthy controls were evaluated serum sclerostin, and was examined the relationship with hematological parameters RBC, Hb, PCV, WBC, PLT, BMI, splenic status, iron, and ferritin levels. The information of beta-thalassemia patients was collected and records by the questioner. Results: A significantly increased serum sclerostin level (mean 26.80±0.91) pg/ml was showed in βT patients compared with the healthy controls (10.03±0.68, p smaller than 0.001) pg/ml. Furthermore, a significant decrease (p smaller than 0.05) of the sclerostin level was observed in β-thalassemia major compared to intermedia β-thalassemia patients. Serum sclerostin level revealed a significant increase in progress age; it is highest in the age group (30-40) year as compared with age group (8-18) and (19-29) year respectively. Sclerostin showed no associations with the RBC, Hb, PCV, and significantly positively correlated (p smaller than 0.05) with serum iron, ferritin levels, WBC, and PLT count. Significantly higher sclerostin levels in splenectomized and underweight groups were observed compared to unsplenectomized and normal-weight groups (p smaller than 0.05) of βT patients. Conclusions: Sclerostin plays an important role in beta-thalassemia patients and can serve as a biomarker associated with the bone pathophysiology and indicator to prevent the continuation of such serious diseases caused by iron overload in these patients.
Read ArticleUNRAVELING THE COMPLEXITIES OF CARDIOVASCULAR MEDICINE: A CONVERSATION WITH DR. PETER MCCULLOUGH (EXTENDED EN-US VERSION)
Background: This interview covers Dr. Peter McCullough’s medical career, experience as an editor of medical journals, and his expertise in areas such as cardiomyopathy, myocarditis, and pericarditis. Aims: The primary aim is to understand Dr. McCullough’s perspectives on various medical topics, including his journey as a cardiologist, the importance of peer review, the phenomenon of Pheidippides cardiomyopathy, the differences between myocarditis and pericarditis, and the significance of ethical principles like the Nuremberg Code and the Declaration of Helsinki. Additionally, the interview aims to explore his concerns about censorship during the COVID-19 pandemic. Methods: The interview follows a question-and-answer format, with the interviewer posing questions to Dr. McCullough on various topics related to his medical career, research interests, and ethical considerations. Results: Dr. McCullough shares his insights on topics such as cardiomyopathy, myocarditis, and pericarditis, emphasizing the importance of peer review, identifying potential biases, and balancing scientific rigor with timely dissemination of findings. He also highlights the significance of the Nuremberg Code and the Declaration of Helsinki in ensuring informed consent and preventing coercion in medical research and treatment. Discussion: Dr. McCullough expresses concerns about censorship during the COVID-19 pandemic, which he believes impacted the ability of medical professionals to freely discuss and disseminate health-related information. He also discusses the potential role of COVID-19 vaccines in causing myocarditis and the need for transparent communication about treatment options and potential complications. Conclusion: The interview provides valuable insights from Dr. McCullough’s extensive medical experience and expertise, covering a range of topics from cardiovascular conditions to ethical principles and the challenges posed by censorship during the COVID-19 pandemic.
Read Article